
1. j infect dis. 2010 apr 15;201(8):1164-8. doi: 10.1086/651381.

clinical virologic efficacy herpes simplex virus type 2 suppression by
acyclovir multicontinent clinical trial.

fuchs j(1), celum c, wang j, hughes j, sanchez j, cowan f, reid s,
delany-moretlwe s, corey l, wald a; hiv prevention trials network 039 protocol
team.

author information: 
(1)hiv research section, san francisco department public health, san
francisco, ca 94102, usa. jonathan.fuchs@sfdph.org

acyclovir suppressive therapy (400 mg twice daily) reduces herpes simplex virus
(hsv) type 2-associated genital ulcer disease lesional hsv shedding. an
international trial acyclovir suppression hsv type 2 prevent human
immunodeficiency virus (hiv) acquisition (hiv prevention trials network 039),
acyclovir smaller effect frequency genital ulcer disease well 
as smaller effect frequency quantity lesional hsv dna african 
women peruvian men, compared effects men united states.
the observed regional variation clinical virologic efficacy of
acyclovir hsv suppression warrants evaluation determinants of
responses acyclovir. (clinicaltrials.gov identifier: nct00076232.).

doi: 10.1086/651381 
pmcid: pmc2856478
pmid: 20214474  [indexed medline]

